Taking a Deep Cleansing Breath: Updates in Management of Chronic Rhinosinusitis with Nasal Polyps



Release date: September 15, 2021
Expiration date: September 15, 2022
Estimated time to complete activity: 1.0 hour(s)



Michael S. Blaiss, MD, FACAAI
Clinical Professor
Medical College of Georgia at Augusta University
Augusta, Georgia


Until recently the only treatment choices for patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery. Researchers realized that the monoclonal antibody treatments developed to treat severe asthma could also be an effective treatment option for CRSwNP.

Nasal polyposis is typically present in patients with the highest levels of disease severity, and endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery. Availability of biologics for CRSwNP gives clinicians treatment options beyond steroids and surgery for their CRSwNP patients who are struggling to breathe freely. However, it also confronts them with new and different decisions. This program has been designed to help clinicians determine when each treatment is most appropriate when treating patients with CRSwNP.


This educational activity has been designed to meet the needs of allergists, immunologists, and specialty nurse practitioners (NPs)/physician assistants (PAs).


Upon completion of this educational activity, participants should be able to:

  • Analyze the phenotypes and endotypes of chronic rhinosinusitis with and without nasal polyps based on what is understood thus far about immunologic pathophysiology and its impact on disease burden
  • Summarize the mechanisms of action of new and emerging targeted biologics for CRSwNP, as well as the efficacy and safety profiles revealed in clinical trials
  • Implement shared decision making with CRSwNP patients to determine when treatment with a biologic, intranasal corticosteroid, or surgery is most appropriate

There are no fees for participating and receiving CME credit for this activity. During the period of September 15, 2021 through September 15, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael S. Blaiss, MD, FACAAI
Consulting Fees: ALK-Abello Inc., GlaxoSmithKline, Merck, Perrigo, Pfizer, Regeneron, Sanofi, TerSera
Speakers’ Bureaus: ALK-Abello Inc., Merck, Regeneron, Sanofi

The Integrity Continuing Education, Inc planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.


Continue to Pretest